|
A Phase I Study of Isolated Hepatic Portal and Arterial Perfusion (IHP) with Escalating Dose Melphalan for Primary or Metastatic Unresectable Cancers of the Liver Clinical Trials References presented on Clinical Trials Search is not intended to be a substitute for proven healthcare advice, trips or professional assistance by using a real medical. We aren't mDs. Always confer with your physician about A Phase I Study of Isolated Hepatic Portal and Arterial Perfusion (IHP) with Escalating Dose Melphalan for Primary or Metastatic Unresectable Cancers of the Liver conditions. Clinical Trials Search.org is a website devoted to listing clinical research studies in human subjects. A Phase I Study of Isolated Hepatic Portal and Arterial Perfusion (IHP) with Escalating Dose Melphalan for Primary or Metastatic Unresectable Cancers of the Liver Clinical research trials and A Phase I Study of Isolated Hepatic Portal and Arterial Perfusion (IHP) with Escalating Dose Melphalan for Primary or Metastatic Unresectable Cancers of the Liver medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectualness of new does drugs. The purpose of the studies / projects is to solve specific human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to discover treatments for all sorts of conditions, such as A Phase I Study of Isolated Hepatic Portal and Arterial Perfusion (IHP) with Escalating Dose Melphalan for Primary or Metastatic Unresectable Cancers of the Liver. A Phase I Study of Isolated Hepatic Portal and Arterial Perfusion (IHP) with Escalating Dose Melphalan for Primary or Metastatic Unresectable Cancers of the Liver Clinical Trials and other clinical trials permit volunteers to access healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for without cost, and every now and again they are compensated for their time. Sometimes there is a cost for a A Phase I Study of Isolated Hepatic Portal and Arterial Perfusion (IHP) with Escalating Dose Melphalan for Primary or Metastatic Unresectable Cancers of the Liver clinical trial. Subjects often receive the most expert healthcare possible for their A Phase I Study of Isolated Hepatic Portal and Arterial Perfusion (IHP) with Escalating Dose Melphalan for Primary or Metastatic Unresectable Cancers of the Liver condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, healthcare dangers (perhaps life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with stern guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Phase I Study of Isolated Hepatic Portal and Arterial Perfusion (IHP) with Escalating Dose Melphalan for Primary or Metastatic Unresectable Cancers of the Liver  A Phase I Study of Isolated Hepatic Portal and Arterial Perfusion (IHP) with Escalating Dose Melphalan for Primary or Metastatic Unresectable Cancers of the Liver
A Phase I Study of Isolated Hepatic Portal and Arterial Perfusion (IHP) with Escalating Dose Melphalan for Primary or Metastatic Unresectable Cancers of the Liver
For Condition: Liver Neoplasms,Neoplasm Metastasis
Status: Completed
Sponsor(s): National Cancer Institute (NCI) ,
Synopsis: Patients with unresectable primary or metastatic cancer confined to the liver will undergo a 1 hour hyperthermic isolated hepatic perfusion (IHP) via the portal vein and hepatic artery with escalating dose melphalan. Patients eligible for this protocol are those with non-colorectal histologies and those with colorectal cancer previously treated with intra-arterial FUDR. Hepatic and systemic toxicity, response to treatment, duration of response, and survival will be followed.
Details: Patients with unresectable primary or metastatic cancer confined to the liver will undergo a 1 hour hyperthermic isolated hepatic perfusion (IHP) via the portal vein and hepatic artery with escalating dose melphalan. Patients eligible for this protocol are those with non-colorectal histologies and those with colorectal cancer previously treated with intra-arterial FUDR. Hepatic and systemic toxicity, response to treatment, duration of response, and survival will be followed.
Eligibility:
Study Type: Interventional, Treatment, Safety
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: Histologically or cytologically proven measurable primary or metastatic non-colorectal cancer limited to the parenchyma of the liver with no evidence of unresectable extrahepatic disease by preoperative radiological studies. Limited resectable extrahepatic disease is acceptable. Patients with colorectal cancer previously treated with intrahepatic arterial infusional therapy using FUDR, those with aberrant arterial anatomy such that infusional therapy is not possible, or those with limited extrahepatic disease such that regional therapy is not indicated will be eligible for this protocol. Patients must have had no chemotherapy, radiotherapy, or biologic therapy for their malignancy in the month prior to the liver perfusion and must have recovered from all side effects. Patients must have an ECOG performance standard of 0, 1 or 2 on the day prior to treatment. Patients must have adequate hepatic function as evidence by bilirubin less than 2.0 and a PT and PTT that are within 1-2 seconds of the upper normal limit. No patients with biopsy proven cirrhosis or evidence of significant portal hypertension by history, endoscopy, or radiologic studies will be included. No patients with a history of congestive heart failure with an LVEF of equal to or less than 40% will be included. No patients with COPD or other chronic pulmonary disease with PFT's less than 50% predicted for age will be included. Patients must be 18 years of age or older. Patients must have a platelet count greater than 100,000, a HCT greater than 27.0, a white blood count greater than 3000/ micrograms, and a creatinine less than or equal to 1.5 or a creatinine clearance of greater than 60 ml/min. No pregnant patients or nursing mothers will be eligible. Patients must not be taking immunosuppressive drugs or on chronic anticoagulation. Patients must not have an active infection. Patients with severe allergic reactions to iodine contrast which can not be controlled by premedication with antihistamines and steroids are not eligible as a hepatic angiogram is needed for this procedure. Patients must not have HIV disease. Patients must be aware of the neoplastic nature of his/her illness, the experimental nature of the therapy, alternative treatments, potential benefits, and risks. The patient must be willing to sign an informed consent. Patients must not have a history of veno occlusive disease.
Total Enrollment: 30
Location and Contact Information:
National Cancer Institute (NCI)
Bethesda, Maryland, 20892
United States
Additional Information:
Study ID Numbers: 970200; 97-C-0200
Study Start Date: September 26, 1997
Record last reviewed: April 1, 2000
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001587
Other Liver Neoplasms Studies:
1. Direct Injection of Alcohol for the Treatment of Spinal Tumors
2. Surgery Versus Radiosurgery to Treat Metastatic Brain Tumors
3. A Phase II Trial of Trastuzumab and Paclitaxel in Patients with HER2 Overexpressing Breast and Ovarian Tumors Who Have Relapsed or Progressive Disease Following Conventional Cytotoxic Chemotherapy Regimens for Metastatic Cancer
4. Studies on Tumors of the Thyroid
5. A Multimodality Treatment Approach to Patients with Inflammatory Cancer of the Breast and Locally Advanced Non-Inflammatory Stage III Breast Cancer and Stage IV Breast Cancer
Related Studies:
Other Liver Neoplasms Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
A Phase I Study of Isolated Hepatic Portal and Arterial Perfusion (IHP) with Escalating Dose Melphalan for Primary or Metastatic Unresectable Cancers of the Liver
|
|
|
|
|
|
|
|
